Scantox

The Big Blue® Transgenic Rodent Somatic and Germ Cell Gene Mutation Assay is offered by Scantox to support mutagenicity assessment in compliance with the OECD 488 guideline in both rats and mice across various tissue types.

A mammalian gene mutation assay conducted under GLP guidelines compliant with OECD 476.

In vitro mammalian cell gene mutation test targeting the hprt locus for detecting mutagenic potential under GLP compliance.

A mammalian cell gene mutation assay evaluating the thymidine kinase locus following OECD 490 standards.

In vitro mammalian cell gene mutation assay assessing structural and numerical chromosomal damage in compliance with OECD 490 and GLP standards.

Customized IL-10 knockout mouse model leading to spontaneous colitis due to an unregulated immune response for specialized studies.

Well-established transgenic mouse model focusing on amyloid precursor protein pathology.

Transgenic mouse model featuring specific readouts for Alzheimer's disease research.

Transgenic mouse model utilized for studying specific aspects of neurodegeneration and Alzheimer's disease.

Transgenic mouse model featuring specific properties regarding amyloid-beta expression patterns and brain pathology.

Transgenic mouse model focusing on tau pathology and neurofibrillary tangle formation.

In vivo animal model service featuring 5xFAD transgenic mice for studying Alzheimer's disease pathology, amyloid-beta plaques, and neurodegeneration.

Transgenic mouse model service expressing APPSL mutations to study learning, memory deficits, and Alzheimer's disease pathogenesis.

A transgenic mouse model designed for amyotrophic lateral sclerosis (ALS) research and therapeutic evaluation.

Comprehensive OECD 471 guideline Ames test for assessing mutation hazards using standard bacterial strains.

An optimised bacterial reverse mutation assay designed to reliably detect the mutagenic potential of N-nitrosamines and NDSRIs with enhanced testing conditions including 30% rat and hamster S9.

An optimized Ames test specifically adapted for challenging compounds such as N-nitrosamines and NDSRIs.

A regulatory in vitro test for chromosomal damage compliant with OECD 487.

Standard regulatory in vitro micronucleus assay detecting both clastogenic and aneugenic modes of action for a test substance.

An optimized genotoxicity screening package incorporating Ames and micronucleus tests.

A comprehensive genetic toxicology screening package combining 24-well Ames and 96-well MNT + FISH assays to assess mutagenic, clastogenic, and aneugenic mechanisms using minimal test item amounts.

A microplate-based micronucleus test utilizing automated slide scoring to enhance throughput and evaluation efficiency.

A 96-well microplate adapted method analysing cells for micronuclei combined with pan-centromeric FISH probes for regulatory assessment.

LC-MS/MS model utilized for analyzing compounds, particularly beneficial for charged species like peptides.

LC-MS/MS model equipped with iFunnel technology to improve signal intensity and accuracy.

Genetically modified Göttingen minipigs carrying a mini-repertoire of human genes for immunoglobulin heavy chains and light chains, designed for non-rodent toxicological testing of therapeutic recombinant antibodies and large molecules.

ISO 10993医療機器ガイドラインに完全に準拠した医療機器の生体内試験および前臨床 in vivo 試験サービス。

Preclinical toxicology services assessing the impact of drugs on the reproductive cycle, fertility, pregnancy, and the development of embryos and fetuses across rodent and non-rodent animal models.

Scantox delivers services in full compliance with the internationally recognized OECD Good Laboratory Practice (GLP) standards, covering toxicology, pharmacokinetics, ADME, and bioanalytical services.

General toxicology studies in rodents and non-rodents, including Maximum Tolerated Dose (MTD), Dose Range Finding (DRF), and repeat-dose toxicity studies.

Comprehensive portfolio of drug discovery, development and CMC/Analytical services including preclinical studies, disease models, exploratory toxicology, PK/PD, and efficacy models.

Preclinical juvenile toxicity studies designed to assess drug safety and efficacy for pediatric use using Göttingen minipigs.

Comprehensive preclinical drug development platform and services for rare diseases, ranging from target identification to safety and toxicology studies.

Preclinical formulation services specializing in transforming active pharmaceutical ingredients (APIs) into effective formulations optimized for safety, bioavailability, and animal models.

An optimized Ames test incorporating enhanced conditions such as rat and hamster S9 at 30% concentration, designed to reliably detect the mutagenic potential of N-nitrosamines and NDSRIs.

Comprehensive general toxicology studies including GLP-accredited acute, subchronic, and chronic safety evaluations using rodent and non-rodent models.

Preclinical wound healing studies performed using Göttingen Minipigs to assess safety, local tolerance, and efficacy for wound dressings, pharmaceuticals, and combination products.

Preclinical efficacy studies and flexible, client-tailored experimental setup and establishment of disease models to meet specific sponsor requirements.

Comprehensive pharmacokinetic (PK) and pharmacodynamic (PD) study services for evaluating and optimizing new drug candidates in early drug discovery and development.

Histopathology evaluations crucial in preclinical testing and pharmaceutical approval processes adhering to GLP conditions.

Analytical method development and quality control testing ensuring safety and efficacy.

Exploratory non-GLP toxicology studies designed to help clients early in the development process to identify and define preclinical efficacy and tolerability.

Preclinical safety assessment and local tolerance testing services evaluating potential local toxicity and kinetic profiles for topical, parenteral, and mucosal administration routes.

LC-MS/MS bioanalysis of small molecules with tailored problem-solving experience for complex bioanalytical challenges.

Special diet-induced mouse models using various genetic backgrounds and diets to induce obesity, diabetes, metabolic syndrome, atherosclerosis, or worsen Alzheimer's or Parkinson's disease pathology.

Advanced error-corrected sequencing service and reagent kits to detect ultra-rare mutations and characterize mutational signatures, providing mutation frequency, spectra, and mechanistic insight.

Preclinical in vitro and in vivo aging, longevity, and senescence research services including rodent models, cognitive impairment models, motor impairment models, and inflammation studies.

Comprehensive formulation development services ensuring optimal delivery and stability of drug candidates.

GMP manufacturing and clinical packaging services to support clinical trials and drug delivery.

In vivo alkaline single cell gel electrophoresis assay to measure DNA strand breaks for genotoxicity and safety assessment.

A rat model used to mimic memory dysfunction observed in dementia and Alzheimer's disease as an initial screening tool to identify therapeutic candidates.

An in vivo animal model allowing rapid evaluation of tau phosphorylation at several residues for Alzheimer's disease and neurodegenerative research.

Services covering pre-formulation to ensure drugability, formulation development, and GMP manufacture of investigational medicinal products for phase 1 and 2 clinical trials.

Mouse xenograft validated standards and tumor models available for drug screening and efficacy studies across various cancer types.

A chemically induced animal model using 2,4,6-trinitrobenzene sulfonic acid to foster significant structural alterations within the colon for drug evaluation.

A cornerstone preclinical colitis model utilizing dextran sodium sulfate administered through drinking water to simulate acute and chronic colitis in mice.

ICH-aligned stability programs to evaluate product shelf-life and degradation pathways under various conditions.

A comprehensive service providing custom in vivo induced disease models across various indications.

A higher-throughput and fast-turnaround technique using flow cytometry to assess micronucleus formation and predict OECD 487 outcomes with low compound usage.

Analysis services in the field of organic chemistry tailored to client specific needs and requirements, including method development and release testing for pharmaceuticals and medical devices.

An in vivo rodent bone marrow micronucleus assay performed in accordance with OECD 474 guidelines.

Scientific evaluation of pharmaceutical products to ensure quality, safety, and efficacy including identity verification, purity assessment, stability testing, and release profiling.

Miniaturized Ames testing options capable of screening multiple compounds using minimal test substance quantities.

A miniaturised Ames assay employing the 6 well format for early identification of potential genotoxicity, allowing clients to reduce cost, de-risk compound development, and make quicker decisions.

Comprehensive non-clinical core battery safety pharmacology studies evaluating cardiovascular, respiratory, and central nervous systems to investigate potential undesirable pharmacodynamic effects of novel drug candidates.

A pre-clinical in vivo animal model using glyceryl trinitrate (nitroglycerin, NTG) injection in mice to induce migraine-like symptoms, used for evaluating the efficacy of potential migraine treatments.

Knock-in mouse model for studying amyloid-beta and Alzheimer's disease pathology.

Screening format designed to detect mutagens while reducing the required quantity of test substance compared to standard full plate assays.

In vitro 3T3 NRU phototoxicity assay to evaluate acute phototoxic potential induced by chemical substances exposed to light.

Wild type C57BL/6 mice receiving a single, unilateral injection of AAV2 hA53T-α-syn into the substantia nigra to selectively express human mutant alpha-synuclein for Parkinson’s disease research.

A flow cytometry-based assay using multiple biomarkers within a single experiment to detect genotoxic stress and distinguish between clastogenic and aneugenic modes of action.

Release testing services for preclinical trials.

Preclinical animal model service using 6-hydroxydopamine induction to simulate Parkinson's disease pathology and motor deficits.

Preclinical animal model service using Col4A3 knockout mice to replicate Alport Syndrome pathology and study renal function.

Pre-formulation work including pH-solubility profile and log P determination.

A high-throughput DNA damage response screening assay using the GADD45a gene coupled with luciferase reporter proteins and the TK6 cell line for genotoxicity assessment.

Robustness testing services for analytical methods.

Inbred mouse model service featuring the BTBR strain for evaluating social behavior, repetitive behaviors, and phenotypes related to autism spectrum disorder.

Fully equipped clinical pathology lab providing analyses of all standard tests and biomarkers within hematology, biochemistry, coagulation, and urinalysis for toxicology studies across multiple species.

Screening service utilizing a 24-well agar-based format for bacterial reverse mutation assay to test for mutagenicity and point mutations.

Stability stress testing services for pharmaceutical products.

An automated 96-well in vitro micronucleus screening assay enhanced with fluorescent in situ hybridization (FISH).

Mice receiving acute, chronic or subchronic administration of MPTP to selectively lose significant numbers of dopaminergic neurons in midbrain structures.

Cryopyrin-associated periodic syndrome mouse model service for studying autoinflammatory diseases and related phenotypic markers.

Reduced liquid microplate format bacterial reverse mutation assay designed for high-throughput mutagenicity testing.

Standard for Exchange of Non-Clinical Data format and terminology used for the submission of preclinical data in support of IND or NDA submissions to the FDA.

Validation of analytical methods according to guidelines.

In vitro seeding assay service to evaluate amyloid-beta oligomerization, aggregation kinetics, and disease-modifying agents.

QC release testing of products for clinical trials under GMP compliance.

An in vivo animal model for studying Parkinson's disease involving rotenone induction.

In vitro testing service designed to measure amyloid-beta and tau aggregation dynamics, as well as test compounds for disaggregation effects.

Quality Control testing of marketed products under GMP compliance.

LC-MS/MS coupled with the ACQUITY Premier chromatographic system designed to improve separation and detection of metal-sensitive analytes.

An animal model used for studying aging processes, senescence, and associated cognitive deficits.

Validation of cleaning procedures for pharmaceutical manufacturing.